Nom du produit:(4-fluorophenyl)-(2-piperazin-1-ylpyrimidin-5-yl)methanone;hydrochloride
IUPAC Name:5-(4-fluorobenzoyl)-2-(piperazin-1-yl)pyrimidine hydrochloride
- CAS:1703795-52-1
- Formule moléculaire:C15H16ClFN4O
- Pureté:95%+
- Numéro de catalogue:CM327493
- Poids moléculaire:322.77
Unité d'emballage |
Stock disponible |
Prix($) |
Quantité |
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:1703795-52-1
- Formule moléculaire:C15H16ClFN4O
- Point de fusion:-
- Code SMILES:O=C(C1=CC=C(F)C=C1)C2=CN=C(N3CCNCC3)N=C2.[H]Cl
- Densité:
- Numéro de catalogue:CM327493
- Poids moléculaire:322.77
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Piperazines
- Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
- Pyrimidines
- Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.
Column Infos
- Avapritinib
- Blueprint Medicines announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe. AYVAKYT was designed to potently and selectively target KIT D816V, the primary underlying driver of the disease.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.